Medtronic plc
Bear Case (25th pct.)
-35.3% vs price
Base Case (Median)
-29.6% vs price
Bull Case (75th pct.)
-5.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $22.74 | -73.0% | High (40%) |
| PE Comparable | $83.04 | -1.4% | Medium (25%) |
| Growth Trajectory DCF | $59.27 | -29.6% | Medium (20%) |
| Graham Number | $56.91 | -32.4% | Medium (40%) |
| EV/EBITDA | $76.53 | -9.1% | Medium (20%) |
| EV/FCF | $136.82 | 62.5% | Medium (20%) |
| Earnings Power Value | $52.02 | -38.2% | Medium (50%) |
Based on 7 out of 8 methods, MDT appears overvalued at the current price of $84.22. The base case fair value of $59.27 implies 29.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.